NurExone’s Exosome Platform Gains Global Spotlight with Dual 2025 Award Nominations

With its nomination for the prestigious Prix Galien Bridges Award 2025, NurExone Biologic Inc. is mentioned in the same breath as industry giants such as Roche Holding AG and Novo Nordisk.

The Galien Foundation uses this new award format to honor organizations that enable significant advances through medical innovation and international collaboration. NurExone, with its exosome therapy platform, embodies precisely this. Its inclusion among the candidates is a strong signal of the growing global visibility of the company’s technology platform.

NurExone: Innovative approaches in regenerative medicine

While Roche reinforces its role as a global market leader with diagnostic solutions such as the cobas i 601 system and the drug EVRYSDI, and Novo Nordisk presents a special therapy for rare diseases with the orphan drug Alhemo, NurExone is taking its own path: The company is developing a biotechnological platform based on biologically active exosomes – these serve as precise transport vehicles for siRNA-based regenerative therapies.

The main product, ExoPTEN, pursues a minimally invasive therapeutic approach: siRNA molecules are delivered precisely into injured nerve tissue via exosomes. There, they are intended to reduce inflammation and activate natural regeneration. The technology offers potential beyond spinal cord injuries – for example, in currently incurable diseases such as glaucoma. This combination of scientific depth and potential for broad application positions NurExone as a promising innovation partner in a network that has been shaped for decades by Roche and Novo Nordisk.

Double award strengthens position in the innovation ecosystem

In addition to being nominated for the Prix Galien Bridges Award, NurExone was also selected as a finalist for the international “Falling Walls Venture – Science Breakthrough of the Year” competition in 2025. This competition recognizes scientific projects with the potential to overcome existing boundaries in medicine, technology, and social innovation. For a young company like NurExone, this double recognition is a strong signal: The exosome-based platform is increasingly being perceived as a promising technology and a potential future standard in regenerative medicine.

Strategically, this underscores the company’s unique role: While Roche and Novo Nordisk consolidate their leading positions through established product portfolios, NurExone is growing into the role of a bridge builder – between academic research, clinical development, and industrial scaling. The nomination for the Prix Galien Bridges Award reflects this strength: innovative capability coupled with global networking.

__

(Featured image by Terry Vlisidis via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in FinanzNachrichten.de. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.